Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDLC versus BPaL for pre-extensively drug-resistant tuberculosis in Pakistan
ISRCTN16037920Phase 3Active, not recruiting
- Sponsor
- Association for Social Development
- Start
- Aug 2025
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bedaquiline, delamanid, linezolid, clofazimine and pretomanid in Tuberculosis (TB), sponsored by Association for Social Development. Started Aug 2025; status: active, not recruiting.
02
Drugs
bedaquilinedelamanidlinezolidclofaziminepretomanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN16037920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16037920.